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Basic fibroblast growth factor (bFGF) is an 18-kDa polypeptide found within the mammalian brain with potent multipotential trophic effects on brain cells. In vitro, bFGF promotes the survival and out growth of a wide variety of neurons from embryonic rat brain and supports the survival and proliferation of brain glia and capillary endothelial cells (Gospo darowicz et al., 1986a; Pettman et al., 1985; Wa licke, 1988) . In the intact brain, bFGF is localized to neurons and glial cells, whereas the high-affinity bFGF receptor (fig) is widely localized on both neu rons as well as non-neuronal cells (Emoto et al., 1989; Finklestein et al., 1988; Gomez-Pinilla et al., 1992; Woodward et al., 1992) . In particular, the density of bFGF receptors is high in vascular brain structures (including circum ventricular organs and choroid plexus), most likely due to their localization ml. No vasodilation was found when bFGF was heat in activated, or preincubated with blocking antibody. Moreover, bFGF-induced vasodilation was attenuated by coadministration of the NO synthase inhibitor �-nitro L-arginine methyl ester (L-NAME), consistent with an NO-dependent mechanism. These results suggest that bFGF may play an important role in the regulation of cerebrovascular tone and cerebral blood flow. Key Words: Basic fibroblast growth factor-NG-nitro-L arginine methyl ester (L-NAME)-Cranial window-Pial arterioles-Vasodilation. on capillary endothelial cells (Wanaka et al., 1990) . Levels of bFGF rise in brain during development and after brain injury or stroke, suggesting a role for this factor in neural outgrowth and glial and vascu lar proliferation ("angiogenesis") occurring during these processes (Caday et al., 1990; Finklestein et al., 1988; Finklestein et al., 1990a,b) . However, the precise role of bFGF in the mature intact brain re mains unknown.
In recent studies, Cuevas et al. (1991) found that the intravenous injection of bFGF in mature rats and rabbits lowered blood pressure by systemic va sodilation; this effect was mediated through nitric oxide (NO)-as well as calcitonin gene-related pep tide (CGRP)-dependent mechanisms. In the current study, we found that topically applied bFGF is a potent dilator of pial arterioles, and that this effect, in part, is also mediated through NO-dependent mechanisms.
MATERIALS AND METHODS

Reagents
Artificial CSF was prepared daily with the following composition: Na+ (156.5 mM) , K+ (2.95 mM), Ca 2 + (1.25 mM) , Mg 2 + (0.67 mM), Cl-(138.7 mM), HC03-(24.6 mM) , dextrose (66.5 mg/dl), and urea (40.2 mg/dl), adjusted to pH 7. 33-7.38 (Levasseur et aI., 1975) . CSF was equilibrated by continuous bubbling with a 10% 0 2 ' 5% CO 2 , and 85% N 2 mixture. Recombinant human bFGF (PeproTech, Inc., Rocky Hill, NJ, U.S.A.) was stored at -85°C as concentrated stocks (1 mg/ml) in phosphate-buffered saline (PBS; Sigma, St. Louis, MO, U.S.A.) with 0.1 mg/ml bovine serum albumin (BSA; Boehringer-Mannheim, Mannheim, Germany), thawed just before use, and diluted to concentrations of 5-200 ng/ml in artificial CSF with 0.1 mg/ml BSA. Vehicle so lutions contained artificial CSF and BSA without bFGF. The bioactivity of bFGF stock solutions was confirmed by mitogenic assay on Balb c/3T3 cells (�7 activity units/ ng) (Sullivan and Klagsbrun, 1986) . Heat-inactivated bFGF (hi bFGF) was prepared by repeatedly heating stock bFGF solutions to 95°C for 15 min six times; lack of activity of hi bFGF was confirmed by Balb c/3T3 assay. Monoclonal anti-bFGF antibody (UBI 117, Upstate Bio chemicals, Lake Placid, NY, U.S.A.) was stored in PBS and 0.1 mg/ml BSA at -85°C. This antibody blocks the mitogenic activity of bFGF (Matsuzaki et aI., 1989) . For antibody blocking experiments, bFGF and antibody so lutions were mixed (50 ng/ml to 50 f.Lg/ml, respectively) and kept at 4°C overnight before use. In some experi ments, NG-nitro-L-arginine methyl ester (L-NAME; Sigma; 10 f.LM) was added to vehicle and bFGF solutions.
Cranial windows
Cranial windows were inserted in male Sprague Dawley rats (280--320 g) as described previously (Levas seur et al., 1975) : Briefly, animals were anesthetized with sodium pentobarbital (50 mg/kg, i.p.), and given pancu ronium bromide (0.5-1.0 mg, Lv.). After tracheostomy, rats were mechanically ventilated (U. Basile ventilator, Varese, Italy) with room air supplemented with oxygen. The femoral artery was cannulated for monitoring of ar terial blood pressure and blood gases. Blood gases were measured 2-3 times in each animal (CIBA Corning Blood Gas Analyzer, Medfield, MA, U.S.A.) before cranial win dow superfusion to insure stability. Mean arterial blood pressure (Gould Instruments, Woburn, MA, U.S.A.) and end tidal CO 2 (Novametrix Medical Systems, Walling ford, CT, U.S.A.) were monitored continuously through out each experiment. Rectal temperature was maintained at 37°C by a thermostatically regulated heating pad (Har vard Apparatus, Natick, MA, U.S.A.).
Mter the head was fixed in a stereotaxic frame, the skull was exposed by a midline skin incision. The perios teum was removed, and the skull was cleaned and cov ered with a thin layer of dental acrylic. A 7 x 5 mm left parietal craniectomy was then made under an operating microscope. The bone was carefully thinned and re moved, and the dura was incised and reflected. A metallic cranial window (Levasseur et aI., 1975) , equipped with three ports to allow rapid addition or removal of bathing fluid as well as measurement of intracranial pressure, was then placed over the exposed pial surface and quickly sealed with bone wax and dental acrylic. The window was filled with artificial CSF (0.6 ml total volume); intracra nial pressure was maintained at 5 mm Hg.
Pial vessels were visualized (magnification = 200X) using an intravital microscope (Leitz, Germany) with il lumination provided by a xenon light source equipped with heat and green light filters. Selected pial arteries (1-3 per animal) were then imaged using a videocamera onto a high-resolution black and white monitor (Series CCD-72 System, Dage MTI, Michigan City, IN, U.S.A.), and ves-sel diameter at selected points was measured by a man ually operated video measurement device (VIA-100, Boeckler Instruments, Tucson, AZ, U.S.A.), or an auto mated video width analyzer (Model C3161, Hamamatsu Photonics, Hamamatsu, Japan). Both devices gave com parable data.
Experimental design
For each experiment, cranial windows were superfused successively with artificial CSF, vehicle, and test solu tions. Arteriolar diameter was measured at each step, al lowing 5-10 min of equilibration with each solution. In experiment I (Expt. I, n = 5 animals), cranial windows were superfused with vehicle, followed by bFGF at in creasing stepwise concentrations (5, 10, 20, 50, 100, and 200 ng/ml) . In Expt. II (n = 4 animals), cranial windows were superfused with vehicle, followed by a single con centration of heat-inactivated bFGF (hi bFGF, 200 ng/ ml); arteriolar diameter was measured repeatedly every 5 min for 40 min. In Expt. III (n = 5 animals), cranial windows were superfused successively with vehicle, bFGF (50 ng/ml), vehicle again, and bFGF (50 ng/ml) pre incubated with blocking antibody (50 f.Lg/ml). Other ani mals were superfused with antibody alone. In Expt. IV (n = 4 animals), cranial windows were superfused with ve hicle (also containing L-NAME [10 f.LM]), followed by increasing stepwise concentrations of bFGF (5-200 ng/ ml) in the presence of L-NAME (10 f.LM).
Data for each vessel were expressed as percent change relative to vehicle ("% of control diameter"). Values from replicate vessels were averaged for each animal, and then averaged among replicate animals for each datum point. Data from Expts. I, II, and IV were analyzed by two-way analysis of variance [ANOV A; (animal x bFGF dose) for Expts. I and IV, (animal x time) for Expt. 11], followed by appropriate two-tailed pooled t tests to de termine differences from the control (vehicle) condition, using the Bonferroni correction for multiple comparisons. Data from Expts. III were analyzed by repeated measures ANOV A, followed by two-tailed paired t tests to appro priate controls with Bonferroni correction.
RESULTS
Physiological data are shown in Table 1 . Mean arterial blood pressure (MABP), P a o 2 , P a co 2 , and pH did not differ between animals in Expts. I-IV. Overall, a total of 31 pial arterioles were examined in 18 animals, with diameter ranging between 25 and 87 j..l. m. Baseline vessel diameters were 49 ± 17, 35 ± 12, 43 ± 2, and 47 ± 7 j..l. m (mean ± SD) for Expts. I, II, III, and IV, respectively.
Basic FGF (5 -200 ng/ml) caused a dose- dependent dilatation of pial arterioles, with maxi mal diameter (-120% of control levels) reached at 100 nglml (Expt. I, Fig. 1 ; F[l/6] = 59.91; p = 0.0001). By contrast, heat-inactivated bFGF (200 ng/ml) produced no significant vasodilation, even up to 40 min after addition (Expt. II, Fig. 1 ; F[1/8] = 1.31; p = n.s.). In antibody blocking experi ments (Expt. III, Fig. 2 ), bFGF alone (50 ng/ml) caused the expected vasodilation (t = 16.92; df = 4; p < 0.001), but preincubation of bFGF with monoclonal antibody (50 fl g/ml) produced no signif icant vasodilation compared with vehicle (t = 1.00; df = 4; p = n.s.). Vehicle, or vehicle + antibody (50 fl glml) produced no change in arterial diameter compared with artificial CSF alone (data not shown). In order to test the hypothesis that bFGF induced vasodilation is mediated through NO dependent mechanisms, cranial windows were su perfused with bFGF (5-200 ng/ml) in the presence of the nitric oxide synthase inhibitor L-NAME (10 fl -\1). L-NAME blunted, but did not completely abolish, the vasodilating effects of bFGF (Expt. IV, Fig. 1 ; F[l/6] = 9.29; p = 0.0003). At this concen tration, L-NAME alone produced no significant change in arterial diameter (data not shown).
DISCUSSION
Our results show that topically applied bFGF is a potent dilator of pial arterioles, with maximal po- .. �.. L-NAME + bFGF ··· 0··· hi bFGF "� " " "" " ? """ " " "" "" r -"""" """"" '"····· ············ tency reached at 100 ng/mI. (Pial veins were not examined in these experiments.) We found no va sodilation when bFGF was heat inactivated, or blocked by preincubation with monoclonal anti body. Moreover, bFGF-induced vasodilation was attenuated by coadministration of the NO synthase inhibitor L-NAME. The concentrations of bFGF used in these studies (5-200 ng/ml) are likely to be comparable to the "physiologic" concentrations of this factor found in the intact rat brain, and following focal brain injury or infarction. Basic FGF is purified from bovine brain at a concentration of 35-50 fl g/kg (Gospo darowicz et aI., 1986b; equivalent to 70-100 ng for a 2-g rat brain), although its relative distribution in extracellular versus intracellular compartments in brain is not known. Basic FGF levels rise 2-7-fold in tissue surrounding focal brain wounds or infarcts during the first 1-3 weeks after injury (Finkle stein et aI., 1990a,b) . Concentrations of 1-10 ng/ml are generally required for the in vitro mitogenic and neuronotrophic effects of bFGF (Gospodarowicz et aI., 1986a; Klagsbrun and Folkman, 1990;  Sullivan and Klagsbrun, 1986) , whereas total doses of 20 ng to 5 fl g administered over 14-28 days have been used in previous studies showing in vivo neu ronotrophic and angiogenic effects of bFGF in brain (Anderson et aI., 1988; Barotte et aI., 1989; Lyons et ai., 1991; Otto and Unsicker, 1990; Puumala et ai., 1990; Yamada et al., 1991) .
The vasodilating effects of bFGF on pial arteri oles appear to be similar to its effects on systemic vessels .. Cuevas et ai. (1991) administered bFGF by single intravenous injection to anesthetized rats (300--1,000 ng) and to anesthetized (3 f.Lg) and con scious rabbits (7-14 f.Lg), and found significant dose dependent decreases in arterial blood pressure (5-50 mm Hg), associated with arteriographically doc umented dilation of large arteries (aorta, femoral arteries, etc). Hypotension induced by a single bFGF injection lasted for as long as 20 min. More over, these investigators found that bFGF-induced hypotension was biphasic with a fast phase (tl/2 = 2-3 s) mediated through an NO-dependent mecha nism, and a slow phase (tllz = 16-19 s) mediated through a CGRP-dependent mechanism (Cuevas et ai., 1991) . Consistent with these results, we found that bFGF-induced dilation of pial arterioles was attenuated by the NO synthase inhibitor L-NAME, at a concentration similar to that shown previously by us to block L-arginine-induced vasodilation (Morikawa et ai., 1992) . These data suggest that bFGF increases NO formation in NO synthase containing endothelial cells and/or perivascular nerve fibers (Nozaki et ai., 1993c) . Whether bFGF stimulates NO synthesis directly through receptor mediated mechanisms, or indirectly through release of other vasoactive substances (e.g., CGRP) re quires further study; blockade of the bFGF re sponse by L-NAME does not distinguish between these two possibilities. Of note, Wei and colleagues (1992) found that NO stimulates CGRP release from trigeminovascular fibers surrounding feline pial ves sels. In these studies, topical CGRP or trigeminalectomy significantly attenuated the in crease in pial arteriolar diameter seen in response to topical nitroprusside and nitroglycerin, but not to adenosine. Also of note is that, in addition to its NO synthase-blocking activity, L-NAME has also been shown recently to block muscarinic acetylcholine receptors (Buxton et ai., 1993) . Thus, our findings of attenuation of bFGF-induced vasodilation by L-NAME do not exclude the participation of ace tylcholine or cholinergic receptors in this process. Reversal of the effects of L-NAME by L-arginine administration would argue more definitively for a central role for NO synthase in bFGF-induced va sodilation.
As noted above, immunohistochemical and in situ hybridization studies show that bFGF is lo cated in neurons and glial cells of the mature rat brain, and at least one of its high-affinity receptors (flg) is found on neurons as well as non-neuronal cells, most likely including capillary endothelia (Emoto et ai., 1989; Finklestein et ai., 1988; Gomez Pinilla et ai., 1992; Wanaka et ai., 1990; Woodward et ai., 1992) . In vitro, bFGF has potent trophic properties on CNS neurons, glia, and endothelia (Gospodarowicz et ai., 1986a; Pettman et ai., 1985; Walicke, 1988) , and it is possible that this factor has survival-promoting effects on these cells in the in tact brain. Moreover, levels of bFGF increase dur ing development and after brain injury or stroke, suggesting that this factor plays a role in the neural sprouting and in the glial and vascular proliferation that occurs during these processes (Caday et ai., 1990; Finklestein et ai., 1988; Finklestein et ai., 1990a,b) . The current results suggest another po tential role for bFGF in the brain, namely regulation of cerebrovascular tone and consequent regulation of cerebral blood flow (CBF). Indeed, our results are consistent with a recent report showing that lo cal superfusion of bFGF onto rabbit cerebral cortex caused a dose-dependent increase in CBF (Regli et ai., 1993) , although the doses used (5 or 25 f.Lg/ animal) were considerably higher than those used in the current study.
As a corollary to its survival-promoting proper ties, bFGF also protects cultured neurons against the effects of several neurotoxins, including excit atory amino acids (EAAs), Ca2+ ionophore, and hypoglycemia (Cheng and Mattson, 1991;  Fink Ie stein et ai., 1993; Freese et ai., 1992; Mattson et ai., 1989) . Because EAA toxicity appears to play an important role in neuronal death following cerebral ischemia (Choi, 1990) , these findings have led to the speculation that bFGF may be neuroprotective against ischemic cell death in vivo. Indeed, in re cent studies, we found that exogenously adminis tered bFGF reduced the size of excitotoxic cerebral lesions and ischemic infarcts in neonatal rats (Nozaki et ai., 1993a,b) , as well as the size of focal ischemic infarcts in mature rats (Koketsu et ai., 1993) . The current findings suggest that the neuro protective effects of bFGF in vivo may also be due to direct effects on cerebral vessels and cerebral blood flow.
